99
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Visual Outcome and Treatment Frequency of Anti-VEGF Therapy Using the Treat-and-Extend and Treatment Cessation Regimen for Exudative Age-Related Macular Degeneration and Pachychoroid Neovasculopathy

ORCID Icon, , , ORCID Icon &
Pages 4405-4418 | Published online: 09 Nov 2021

References

  • Bourne RRA, Jonas JB, Bron AM, et al. Prevalence and causes of vision loss in high-income countries and in eastern and central Europe in 2015: magnitude, temporal trends and projections. Br J Ophthalmol. 2018;102(5):575–585. doi:10.1136/bjophthalmol-2017-311258
  • Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–e116. doi:10.1016/S2214-109X(13)70145-1
  • Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology. 2010;117(5):921–927. doi:10.1016/j.ophtha.2009.10.007
  • Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481
  • Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444. doi:10.1056/NEJMoa062655
  • Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2357–2548. doi:10.1016/j.ophtha.2012.09.006
  • Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143(4):566–583. doi:10.1016/j.ajo.2007.01.028
  • Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143(4):679–680. doi:10.1016/j.ajo.2007.02.024
  • Engelbert M, Zweifel SA, Freund KB. ‘Treat and extend’ dosing of intravitreal anti-vascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina. 2009;29(10):1424–1431. doi:10.1097/IAE.0b013e3181bfbd46
  • Singh RP, Stone TW, Hahn P, eds. 2019 Global Trends in retina Survey. Chicago, IL: American Society of retina specialists; 2019. Available from: https://www.asrs.org/international/global-trends-in-retina. Accessed November 1, 2021.
  • Gupta O, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology. 2010;117(11):2134–2140. doi:10.1016/j.ophtha.2010.02.032
  • Engelbert M, Zweifel SA, Freund KB. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified “treat and extend” dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina. 2010;30(9):1368–1375. doi:10.1097/IAE.0b013e3181d50cbf
  • Abedi F, Wickremasinghe S, Islam AF, Inglis KM, Guymer RH. Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. Retina. 2014;34(8):1531–1538. doi:10.1097/IAE.0000000000000134
  • Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015;122(1):146–152. doi:10.1016/j.ophtha.2014.07.041
  • Wykoff CC, Croft DE, Brown DM, et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology. 2015;122(12):2514–2522. doi:10.1016/j.ophtha.2015.08.009
  • Arnold JJ, Campain A, Barthelmes D, et al. Two-year outcomes of “treat and extend” intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology. 2015;122(6):1212–1219. doi:10.1016/j.ophtha.2015.02.009
  • Matsumoto H, Morimoto M, Mimura K, Ito A, Akiyama H. Treat-and-extend regimen with aflibercept for neovascular age-related macular degeneration: efficacy and macular atrophy development. Ophthalmol Retina. 2018;2(5):462–468. PMID: 31047326. doi:10.1016/j.oret.2017.09.002
  • Adrean SD, Chaili S, Grant S, Pirouz A. Recurrence rate of choroidal neovascularization in neovascular age-related macular degeneration managed with a treat-extend-stop protocol. Ophthalmol Retina. 2018;2(3):225–230. PMID: 31047590. doi:10.1016/j.oret.2017.07.009
  • Berg K, Roald AB, Navaratnam J, Bragadóttir R. An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration. Acta Ophthalmol. 2017;95(8):796–802. doi:10.1111/aos.13522
  • Silva R, Berta A, Larsen M, Macfadden W, Feller C, Monés J. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND Study. Ophthalmology. 2018;125(1):57–65. doi:10.1016/j.ophtha.2017.07.014
  • Matsumoto H, Hiroe T, Morimoto M, Mimura K, Ito A, Akiyama H. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and type 1 neovascular age-related macular degeneration. Jpn J Ophthalmol. 2018;62(2):144–150. doi:10.1007/s10384-018-0562-0
  • Arendt P, Yu S, Munk MR, Ebneter A, Wolf S, Zinkernagel MS. Exit strategy in a treat-and-extend regimen for exudative age-related macular degeneration. Retina. 2018;39(1):27–33. doi:10.1097/IAE.0000000000001923
  • Traine PG, Pfister IB, Zandi S, Spindler J, Garweg JG. Long-term outcome of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a “treat-and-extend” regimen. Ophthalmol Retina. 2019;3(5):393–399. doi:10.1016/j.oret.2019.01.018
  • Ohji M, Lanzetta P, Korobelnik JF, et al. Efficacy and treatment burden of intravitreal aflibercept versus intravitreal ranibizumab treat-and-extend regimens at 2 years: network meta-analysis incorporating individual patient data meta-regression and matching-adjusted indirect comparison. Adv Ther. 2020;37(5):2184–2198. PMID: 32222903; PMCID: PMC7467478. doi:10.1007/s12325-020-01298-x
  • Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y; Terano Y for the ALTAIR investigators. Efficacy and safety of intravitreal aflibercept treat- and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR. a randomized controlled trial. Adv Ther. 2020;37(3):1173–1187. doi:10.1007/s12325-020-01236-x
  • Ying G, Maguire MG, Daniel E, Huang J, Martin D. Association of baseline characteristics and early vision response with 2-year vision outcomes in the comparison of AMD treatments trials (CATT). Ophthalmology. 2015;122(12):2523–31.e1. doi:10.1016/j.ophtha.2015.08.015
  • Maguire MG, Martin DF, Ying G-S; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Five-year outcomes with anti–vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(8):1751–1761. doi:10.1016/j.ophtha.2016.03.045
  • Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy. Retina. 2013;33(8):1659–1672. doi:10.1097/IAE.0b013e3182953df4
  • Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina. 2015;35(1):1–9. doi:10.1097/IAE.0000000000000331
  • Miyake M, Ooto S, Yamashiro K, et al. Pachychoroid neovasculopathy and age-related macular degeneration. Sci Rep. 2015;5(1):16204. doi:10.1038/srep16204
  • Hosoda Y, Yoshikawa M, Miyake M, et al. CFH and VIPR2 as susceptibility loci in choroidal thickness and pachychoroid disease central serous chorioretinopathy. Proc Natl Acad Sci U S A. 2018;115(24):6261–6266. doi:10.1073/pnas.1802212115
  • Yamashiro K, Hosoda Y, Miyake M, Ooto S, Tsujikawa A. Characteristics of pachychoroid diseases and age-related macular degeneration: multimodal imaging and genetic backgrounds. J Clin Med. 2020;9(7):2034. doi:10.3390/jcm9072034
  • Antiplatelet trialist collaboration. Collaborative overview of randomised trials of antiplatelet therapy prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308(6921):81–106. doi:10.1136/bmj.308.6921.81
  • Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti–vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes. Ophthalmol Retina. 2020;4(1):19–30. doi:10.1016/j.oret.2019.05.017
  • Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118(4):663–671. PMID: 21459217. doi:10.1016/j.ophtha.2010.12.019
  • Kuroda Y, Yamashiro K, Miyake M, et al. Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study. Ophthalmology. 2015;122(11):2303–2310. PMID: 26271842. doi:10.1016/j.ophtha.2015.06.053
  • Ohnaka M, Nagai Y, Sho K, et al. A modified treat-and-extend regimen of aflibercept for treatment-naïve patients with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2017;255(4):657–664. doi:10.1007/s00417-016-3507-7
  • Mantel I, Niderprim SA, Gianniou C, Deli A, Ambresin A. Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. Br J Ophthalmol. 2014;98(9):1192–1196. doi:10.1136/bjophthalmol-2013-304556
  • Nishikawa K, Oishi A, Hata M, et al. Four-year outcome of aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Sci Rep. 2019;9(1):3620. doi:10.1038/s41598-019-39995-5.0
  • Ritter M, Simader C, Bolz M, et al. Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy. Br J Ophthalmol. 2014;98(12):1629–1635. doi:10.1136/bjophthalmol-2014-305186
  • Waldstein SM, Wright J, Warburton J, Margaron P, Simader C, Schmidt-Erfurth U. Predictive value of retinal morphology for visual acuity outcomes of different ranibizumab treatment regimens for neovascular AMD. Ophthalmology. 2016;123(1):60–69. doi:10.1016/j.ophtha.2015.09.013
  • Waldstein SM, Simader C, Staurenghi G, et al. Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials. Ophthalmology. 2016;123(7):1521–1529. doi:10.1016/j.ophtha.2016.03.037
  • Ashraf M, Souka A, Adelman RA. Age-related macular degeneration: using morphological predictors to modify current treatment protocols. Acta Ophthalmol. 2018;96(2):120–133. doi:10.1111/aos.13565
  • Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046–1056. PMID: 23352196. doi:10.1016/j.ophtha.2012.10.014
  • Muether PS, Hermann MM, Dröge K, Kirchhof B, Fauser S. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am J Ophthalmol. 2013;156(5):989–993. doi:10.1016/j.ajo.2013.06